|
GOLPH3L expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.30780000162645E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.02509999991385E-07 |
| Normal-vs-Stage2 |
4.835000E-04 |
| Normal-vs-Stage3 |
6.55929999981986E-07 |
| Normal-vs-Stage4 |
6.67170000356876E-08 |
| Stage1-vs-Stage2 |
7.802200E-01 |
| Stage1-vs-Stage3 |
5.245800E-01 |
| Stage1-vs-Stage4 |
5.720500E-02 |
| Stage2-vs-Stage3 |
5.001000E-01 |
| Stage2-vs-Stage4 |
1.163390E-01 |
| Stage3-vs-Stage4 |
2.887200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.63430002864118E-09 |
| Normal-vs-AfricanAmerican |
2.652400E-02 |
| Normal-vs-Asian |
1.50514999999185E-05 |
| Caucasian-vs-AfricanAmerican |
1.224750E-01 |
| Caucasian-vs-Asian |
8.853400E-01 |
| AfricanAmerican-vs-Asian |
1.757550E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.1193999999447E-07 |
| Normal-vs-Female |
5.67510000104576E-08 |
| Male-vs-Female |
5.303800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
7.59750000023374E-07 |
| Normal-vs-Age(41-60Yrs) |
6.85219999629894E-08 |
| Normal-vs-Age(61-80Yrs) |
3.54800000001987E-06 |
| Normal-vs-Age(81-100Yrs) |
3.279600E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
8.240800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.959400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.665000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
8.507000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.775600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.676400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.941840E-02 |
| Classical-VS-Follicular |
8.710200E-01 |
| Classical-VS-Other |
2.887400E-01 |
| Classical-VS-Normal |
7.75520000440011E-08 |
| Tall-VS-Follicular |
5.329600E-02 |
| Tall-VS-Other |
9.195600E-01 |
| Tall-VS-Normal |
7.84999999448033E-08 |
| Follicular-VS-Other |
3.845000E-01 |
| Follicular-VS-Normal |
2.621600E-04 |
| Other-VS-Normal |
8.235200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.92150000033875E-07 |
| Normal-vs-N1 |
2.27759999749111E-08 |
| N0-vs-N1 |
2.656200E-02 |
|
|
